知镜 Cognispect · 医学文献与研究工作台

Diffuse Gastric and Lobular Breast Cancer Syndrome

Barbosa-Matos R, Córdova L, Schrader K, Oliveira C.
· 2026-10-13 · PMID 20301318

文献摘要

Clinical characteristics Diffuse gastric and lobular breast cancer syndrome (DGLBCS) is associated with an increased risk, in males and females, of diffuse gastric cancer (DGC), a poorly differentiated adenocarcinoma (also referred to as signet ring cell carcinoma or isolated cell-type carcinoma) that infiltrates into the stomach wall, causing thickening of the wall (linitis plastica) without forming a distinct mass. In females with CDH1-related DGLBCS, but not in males, there is also an increased risk for lobular breast cancer (LBC), characterized by small, non-cohesive cells dispersed in the stroma or arranged in single-file infiltrating patterns. Cleft lip with or without cleft palate has also been reported in some individuals with CDH1-related DGLBCS. Diagnosis/testing The diagnosis of DGLBCS can be established in an individual with suggestive findings and a germline heterozygous pathogenic variant in CDH1 or a germline heterozygous truncating pathogenic variant in CTNNA1 identified by molecular genetic testing. Affected individuals from families that meet consensus genetic testing criteria for DGLBCS who do not have an identified pathogenic variant in CDH1 or CTNNA1 have suspected DGLBCS of unknown genetic cause (also referred to as hereditary diffuse gastric cancer [HDGC]-like). Management Targeted therapy: Prophylactic gastrectomy for diffuse gastric cancer is an option from early adulthood in individuals with normal endoscopy / gastric biopsies and a DGLBCS-related CDH1 pathogenic variant regardless of family history or a DGLBCS-related CTNNA1 pathogenic variant and a family history of DGC and/or LBC. Supportive care: Management of DGLBCS requires a multidisciplinary team. Standard treatment to eradicate H pylori infection; total gastrectomy for early or advanced DGC; perioperative and/or adjuvant therapy for advanced DGC; surgery, hormonal therapy, and perioperative and/or adjuvant chemotherapy for LBC; consider risk-reducing contralateral mastectomy; standard treatments for cleft correction by craniofacial specialists. Surveillance: For individuals with CDH1- or CTNNA1-related DGLBCS, referral to a high-risk gastric screening program with a thorough ≥30-minute upper endoscopy with multiple targeted and random biopsies every six to 12 months beginning in early adulthood or five to ten years prior to the earliest gastric cancer diagnosis in the family. For females with CDH1-related DGLBCS or CTNNA1-related DGLBCS and personal or family history of breast cancer, referral to a high-risk breast cancer screening program with monthly self-breast exams beginning at age 20 years; annual clinical breast examinations, education on clinical features of breast cancer, and bilateral breast MRI with contrast from age 30 years; annual mammography between MRI screens from age 30-40 years; if MRI is unavailable, breast ultrasound should be combined with mammogram. In individuals with CDH1-related cleft lip/palate, annual audiology and speech evaluation throughout childhood. In individuals with suspected DGLBCS of unknown cause (also referred to as HDGC-like), referral to a high-risk gastric screening program with a thorough ≥30-minute upper endoscopy with multiple targeted and random biopsies annually beginning at age 40 years or ten years prior to the earliest gastric cancer diagnosis in the family; endoscopy interval can be increased after two consecutive normal biopsies at the discretion of the endoscopist. Referral to a high-risk breast cancer screening program; in those with a personal or family history of breast cancer of any type, monthly self-exams beginning at age 20 years, annual clinical breast exam and education of clinical features of breast cancer beginning at age 30 years; additional breast screening as recommended by high-risk breast cancer specialists. Evaluation of relatives at risk: Offer at-risk relatives of a proband with CDH1- or CTNNA1-related DGLBCS predictive testing for the familial pathogenic variant. This will allow identification of individuals who would benefit from intensive surveillance for early cancer detection and/or prophylactic surgeries targeting organs associated with DGLBCS. Offer first-degree relatives of a proband with suspected DGLBCS of unknown genetic cause (HDGC-like) surveillance tailored to the individual's personal and family history. Pregnancy management: Nutritional consequences of total gastrectomy should be discussed before and during pregnancy. Pregnancy should be delayed at least six to 12 months after total gastrectomy, to allow for weight stabilization and nutritional recovery. Genetic counselling DGLBCS is inherited in an autosomal dominant manner. The majority of individuals diagnosed with CDH1-related DGLBCS inherited the CDH1 pathogenic variant from a parent (because of reduced penetrance, the parent from whom the pathogenic variant was inherited may not have developed cancer). Some individuals diagnosed with CTNNA1-related DGLBCS have an affected first- or second-degree relative with gastric or breast cancer. Some individuals with DGLBCS have the disorder as the result of a de novo pathogenic variant. Each child of an individual with DGLBCS has a 50% chance of inheriting the DGLBCS-related pathogenic variant. If the DGLBCS-related pathogenic variant has been identified in an affected family member, predictive testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.

在知镜精读原文来源

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。